Amylo-AFFECT-QOL, a self-reported questionnaire to assess health-related quality of life and to determine the prognosis in cardiac amyloidosis.
cardiac amyloidosis
prognosis
quality of life
self-reported questionnaire
transthyretin
Journal
Frontiers in cardiovascular medicine
ISSN: 2297-055X
Titre abrégé: Front Cardiovasc Med
Pays: Switzerland
ID NLM: 101653388
Informations de publication
Date de publication:
2023
2023
Historique:
received:
15
12
2022
accepted:
10
02
2023
medline:
1
4
2023
entrez:
31
3
2023
pubmed:
1
4
2023
Statut:
epublish
Résumé
Self-reported questionnaires are useful for estimating the health-related quality of life (HR-QoL), impact of interventions, and prognosis. To our knowledge, no HR-QoL questionnaire has been developed for cardiac amyloidosis (CA). This study aimed to validate Amylo-AFFECT-QOL questionnaire to assess HR-QoL and its prognostic value in CA. A self-reported questionnaire, "Amylo-AFFECT" had been designed and validated for CA symptoms evaluation and screening by physicians. It was adapted here to assess HR-QoL (Amylo-AFFECT-QOL) and its prognostic value in CA. To validate the theoretical model, internal consistency and convergent validity were assessed, particularly correlations between Amylo-AFFECT-QOL and the HR-QoL Minnesota Living Heart Failure (MLHF) questionnaire. Amylo-AFFECT-QOL was completed by 515 patients, 425 of whom (82.5%) had CA. Wild-type and hereditary transthyretin amyloidosis (ATTRwt and ATTRv) and immunoglobulin light-chain amyloidosis (AL) were diagnosed in 47.8, 14.7, and 18.8% of cases, respectively. The best HR-QoL evaluation was obtained with five dimensions: "Heart failure," "Vascular dysautonomia," "Neuropathy," "Ear, gastrointestinal, and urinary dysautonomia," and "Skin or mucosal involvement." The global Amylo-AFFECT-QOL and MLHF scores showed significant positive correlations (rs = 0.72, Amylo-AFFECT-QOL demonstrates good psychometric properties and is useful for quantifying HR-QoL and estimating CA prognosis. Its use may help to improve overall management of patients with CA.
Sections du résumé
Background and aims
UNASSIGNED
Self-reported questionnaires are useful for estimating the health-related quality of life (HR-QoL), impact of interventions, and prognosis. To our knowledge, no HR-QoL questionnaire has been developed for cardiac amyloidosis (CA). This study aimed to validate Amylo-AFFECT-QOL questionnaire to assess HR-QoL and its prognostic value in CA.
Methods
UNASSIGNED
A self-reported questionnaire, "Amylo-AFFECT" had been designed and validated for CA symptoms evaluation and screening by physicians. It was adapted here to assess HR-QoL (Amylo-AFFECT-QOL) and its prognostic value in CA. To validate the theoretical model, internal consistency and convergent validity were assessed, particularly correlations between Amylo-AFFECT-QOL and the HR-QoL Minnesota Living Heart Failure (MLHF) questionnaire.
Results
UNASSIGNED
Amylo-AFFECT-QOL was completed by 515 patients, 425 of whom (82.5%) had CA. Wild-type and hereditary transthyretin amyloidosis (ATTRwt and ATTRv) and immunoglobulin light-chain amyloidosis (AL) were diagnosed in 47.8, 14.7, and 18.8% of cases, respectively. The best HR-QoL evaluation was obtained with five dimensions: "Heart failure," "Vascular dysautonomia," "Neuropathy," "Ear, gastrointestinal, and urinary dysautonomia," and "Skin or mucosal involvement." The global Amylo-AFFECT-QOL and MLHF scores showed significant positive correlations (rs = 0.72,
Conclusion
UNASSIGNED
Amylo-AFFECT-QOL demonstrates good psychometric properties and is useful for quantifying HR-QoL and estimating CA prognosis. Its use may help to improve overall management of patients with CA.
Identifiants
pubmed: 36998975
doi: 10.3389/fcvm.2023.1124660
pmc: PMC10043221
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1124660Informations de copyright
Copyright © 2023 Kharoubi, Bézard, Broussier, Galat, Gounot, Poullot, Molinier-Frenkel, Fanen, Funalot, Itti, Lemonnier, Sing Chadha, Guendouz, Mallet, Zaroui, Audard, Audureau, Le Corvoisier, Hittinger, Planté Bordeneuve, Lefaucheur, Amiot, Bequignon, Bartier, Leroy, Teiger, Oghina and Damy.
Déclaration de conflit d'intérêts
TD received grants or consultancy fees from Akcea, Alnylam, Pfizer, and GSK. SO received honoraria from Pfizer. BF received consultancy fees from Pfizer. EI received honoraria from Pfizer and Janssen-Cilag. RG received honoraria from SANOFI. AB received consultancy fees from Pfizer, Novartis, Vifor Pharma, and AstraZeneca. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Muscle Nerve. 2017 Mar;55(3):323-332
pubmed: 27422379
J Clin Oncol. 2004 Sep 15;22(18):3751-7
pubmed: 15365071
J Am Coll Cardiol. 2016 Sep 6;68(10):1014-20
pubmed: 27585505
Am J Hematol. 2017 May;92(5):435-440
pubmed: 28181278
Muscle Nerve. 2019 Aug;60(2):169-175
pubmed: 31093980
J Nurs Scholarsh. 2017 Sep;49(5):513-520
pubmed: 28755434
J Peripher Nerv Syst. 2014 Jun;19(2):104-14
pubmed: 24738700
Am J Cardiol. 1993 May 1;71(12):1106-7
pubmed: 8475878
Eur J Clin Invest. 2021 Nov;51(11):e13598
pubmed: 33982288
Amyloid. 2017 Sep;24(3):194-204
pubmed: 28758793
Am Heart J. 1992 Oct;124(4):1017-25
pubmed: 1529875
Am J Cardiol. 2021 Feb 15;141:98-105
pubmed: 33220323
Circulation. 2016 Jun 14;133(24):2404-12
pubmed: 27143678
Eur J Heart Fail. 2020 Mar;22(3):507-515
pubmed: 31975495
J Am Coll Cardiol. 2000 Apr;35(5):1245-55
pubmed: 10758967
ESC Heart Fail. 2019 Feb;6(1):3-9
pubmed: 30311454
ESC Heart Fail. 2021 Dec;8(6):5501-5512
pubmed: 34714605
Heart. 2002 Mar;87(3):235-41
pubmed: 11847161
Oxf Med Case Reports. 2021 Aug 13;2021(8):omab059
pubmed: 34408883
Orphanet J Rare Dis. 2014 Apr 27;9:61
pubmed: 24767411
Circulation. 2019 Jul 2;140(1):16-26
pubmed: 31109193
Open Heart. 2016 Feb 08;3(1):e000289
pubmed: 26870387
Arch Cardiovasc Dis. 2013 Oct;106(10):528-40
pubmed: 24070600
Eur Heart J. 2019 Apr 01;:
pubmed: 30938420
Bone Marrow Transplant. 2021 Jan;56(1):274-277
pubmed: 32623446
J Clin Oncol. 2012 Mar 20;30(9):989-95
pubmed: 22331953